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Toll-like receptors (TLRs) are important innate immune receptors for the identiﬁcation and clearance of invading pathogens.
Twelve TLRs that recognize various conserved components of microorganisms are currently known. Among these, the endosomal
TLRs 3, 7/8, and 9 recognize dsRNA, ssRNA, and CpG DNA, respectively. Nucleic acid-sensing TLRs, TLR 7 in particular, have
been implicated in systemic lupus erythematosus (SLE) and are thought to exacerbate disease pathology. Activation of these TLRs
results in the production of inﬂammatory cytokines and type I interferon. Genome-wide association studies, single nucleotide
polymorphism analyses as well as experimental mouse models have provided evidence of TLR signaling involvement in SLE and
other autoimmune diseases. Since activation of these receptor pathways promotes autoimmune phenotypes, inhibitory drugs that
target these pathways constitute important new therapeutic strategies for the treatment of systemic autoimmunity.
1.Introduction
Toll-like receptors (TLRs) are pattern recognition recep-
tors of the innate immune system that recognize speciﬁc
pathogen-associated molecular patterns (PAMPs) conserved
among microorganisms. There are currently twelve known
TLRs in mammals, which identify common constituents
of invading pathogens including double-stranded and
single-stranded RNA, unmethylated CpG DNA, bacterial
lipopolysaccharide (LPS), lipoproteins, and ﬂagellin [1].
Upon interaction with their ligands, TLRs signal through
adapter proteins, most commonly Myeloid Diﬀerentia-
tion Primary Response Gene 88 (MyD88), though TLR
3 alternatively signals via the TIR-Domain Containing
Adaptor Inducing Interferon-β (TRIF) adapter [2]. These
adaptersrecruitothermoleculestoinitiatesignalingcascades
ultimately leading to the production of proinﬂammatory
cytokines and type I IFN [3]. These TLR responses are
important in the functioning of both the innate and adaptive
arms of immunity [4, 5].
Although TLRs are important for antimicrobial immu-
nity, they have also been implicated in the pathogenesis
of autoimmune diseases. For example, TLRs 2 and 4 have
been identiﬁed as factors involved in the onset of type
I diabetes mellitus [6–9], and TLRs 1–6 are expressed
by rheumatoid arthritis (RA) synovial ﬁbroblasts and are
thought to provoke joint inﬂammation in RA [10, 11].
Moreover, the nucleic acid binding TLRs 7 and 9 have been
connected to both human and mouse models of systemic
lupus erythematosus (SLE) [12–17]. Because of these links
between TLRs and autoimmunity, a great deal of work has
been directed toward understanding how these receptors
act in disease progression. Two major possibilities arise in
describing how TLRs might work in autoimmunity; either
they are stimulated by exogenous antigens, like viral ssRNA,
which then stimulate resident immune cells, or the TLRs
recognize endogenous self-antigens to initiate and propagate
inﬂammation and autoimmunity.
The accumulation of evidence pointing towards TLRs in
autoimmunity has opened the door for potential therapeutic
interventions directed towards the modulation of Toll-like
receptors and their signaling pathways. Since TLRs are
normally responsive to microbial pathogens, there has been
some speculation as to the application of TLR agonists
as vaccine adjuvants to stimulate more robust immune
responses [18, 19]. On the other side of the spectrum, for
autoimmunity, disease can result from aberrant hyperac-
tive signaling; therefore, the application of inhibitory, or2 Mediators of Inﬂammation
antagonistic, TLR therapeutics is of considerable interest. A
few inhibitors have been developed already and show some
promise for potential human therapeutics. The focus of this
paper is to summarize the present literature documenting
how modulation of Toll-like receptor pathways may be
used as potential methods of treatment for autoimmunity,
particularly SLE.
2. TLR FunctionandSignaling
TLRs are localized to either the cell surface or endosomes of
several cell types, most notably of antigen-presenting cells
(APCs) such as dendritic cells [20, 21] and B cells [22].
Under normal circumstances, TLRs aid in the identiﬁcation
and removal of materials that may be detrimental to the
host organism; these are usually of bacterial, viral, fungal, or
protozoan origin [1, 23]. Because TLRs recognize common
molecular motifs instead of speciﬁc peptide sequences, they
maintain capacity for recognition of a broad repertoire of
microbes. We know, with relative certainty, what most of
the TLRs recognize and that the end result is inﬂammation,
but how does this occur? The cascade by which TLRs
induce an inﬂammatory environment varies depending on
the particular TLR that is stimulated. Since we are more
concernedwithSLE,wewillconcentrateonthesignalingthat
takes place upon activation of nucleic acid-binding TLRs 3,
7/8, and 9.
TLRs exist as dimers or heterodimers with the capacity
to engage their respective ligands. Ligand binding is thought
to induce a conformational change resulting in interaction
or close juxtaposition of the two cytosolic Toll/IL-1 receptor
(TIR) domains, thus providing an interface for adaptor
protein binding and subsequent signal transduction [24]. As
described by several groups, MyD88 is the most common of
these adaptors and has been shown to be involved in sig-
naling through all TLRs except TLR 3 [24–27]. This adapter
protein provides a scaﬀold for further interaction with IL-
1R-associated kinase (IRAK) 1 and 4 to propagate the signal
todownstreameﬀectorsviaphosphorylation.Oncerecruited
to the adaptor protein, IRAK4 is activated. IRAK4, in turn,
activates IRAK1 via phosphorylation [28]. These activated
kinases recruit tumor necrosis factor receptor-associated
factor (TRAF) 6, which is an E3 ubiquitin ligase required for
activation of NFκB by freeing it from its inhibitor, IκB[ 29].
In addition to this, interferon regulatory factors (IRFs) 5 and
7 are also recruited to the MyD88/IRAK/TRAF6 complex,
where they can become phosphorylated and activated [30].
Ultimately, the activation of transcription factors NFκBa n d
IRFs 5 and 7 results in their translocation into the nucleus
where they initiate gene transcription and production of
proinﬂammatory cytokines and type I IFN (Figure 1)[ 3, 31–
35].
TLR 3 signaling is distinct from the previously described
TLR 7 and 9 signaling pathways. Instead of utilizing MyD88
as an adaptor protein, TLR 3 uses TRIF [2]. As with
MyD88, TRIF also recruits additional proteins necessary






IRF 5 IRF 7 NFκB
Type I IFN Proinﬂammatory
cytokines
Figure 1: TLR7/9 Signaling pathway leading to the production of
proinﬂammatory cytokines and type I IFN. Receptor recognizes
nucleic acid ligand and recruits adaptor protein MyD88. MyD88
attracts kinases IRAK1 and IRAK4 to the complex, which can
then activate TRAF6. Activated TRAF6 leads to the stimulation of
transcription factors NFκB, IRF5, and IRF7 to produce cytokines
and type I IFN. IRF7 has been identiﬁed as the primary factor in
production of type I IFN, but there is evidence that IRF5 can also
contribute to type I IFN production [36].
andreceptor-interactingprotein1(RIP1)[24].TRIFinterac-
tion with TBK1 is necessary for the activation of IRF3, which
is a transcription factor involved in the production of IFN-β
[37].TLR3canalsoactivateNFκBbytheinteractionofTRIF
with TRAF6 or RIP1, which allow the transcription factor
to migrate to the nucleus to induce target gene transcription
[24, 28].
The multiple proteins involved in TLR signaling yield
many opportunities to inhibit this process. Several endoge-
nous inhibitors have been identiﬁed that halt, or at least
impair, the signaling cascade, dampening the TLR-mediated
production of inﬂammatory cytokines and type I IFN.
The ability to modulate TLR signaling helps to maintain a
homeostatic balance important for antimicrobial immunity
while also preventing collateral damage to self-tissues. The
inhibitoryproteinsimportantinthisprocesstargettherecep-
tors themselves, adapter molecules, and key kinases, as well
as transcription factors to diminish the TLR-mediated pro-
duction of inﬂammatory cytokines and type I IFN. Triad3A
acts as an E3 ubiquitin ligase promoting the degradation of
TLR 4 and 9. The degradation of these TLRs was shown
to impair NFκB activity upon stimulation with LPS and
CpG DNA whereas siRNA knockdown of Triad3A enhanced
LPS and CpG DNA-mediated NFκBa c t i v i t y[ 38] indicating
a prominent role of Triad3A in modulating TLR response.
Although Triad3A appears to act speciﬁcally on TLR 4 and
9, other inhibitors provide a more global impact on TLR
signaling. As mentioned earlier, MyD88 is an adapter protein
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with LPS or TNF, a splice-variant of MyD88, MyD88s, can be
induced which prevents activation of NFκB[ 39]. This short
form of MyD88 fails to recruit IRAK4, impairing the ability
to phosphorylate IRAK1, therefore preventing the activation
of NFκB[ 39], although maintaining the ability to activate
the transcription factor AP-1 [40]. In addition, recently,
An et al. found that the phosphatase, SHP-1, selectively
impairs activation of NFκB and subsequent production
of proinﬂammatory cytokines while also inhibiting IRAK1
resulting in an increase in IFN-β [41]. Several other factors
have inhibitory roles directed to the active IRAK kinases.
Kobayashi et al. showed that IRAK-M, which lacks the kinase
activity of its counterparts IRAK1 and IRAK4, suppresses
the production of proinﬂammatory cytokines and proposed
a model whereby IRAK-M prevents the dissociation of
the IRAK1/IRAK4/MyD88 complex to inhibit downstream
NFκBa c t i v a t i o n[ 42]. Likewise, the splice variant IRAK1c
acts in a similar manner by interacting with MyD88 and
IRAK4. Like IRAK-M, IRAK1c cannot be phosphorylated by
IRAK4 and thereby inhibits the dissociation of the complex,
preventing activation of NFκB[ 43]. Two other inhibitors
have been identiﬁed downstream of the IRAKkinases: tumor
necrosis factor-α-induced protein 3 (TNFAIP3, or A20) and
IRF4. A20 is a ubiquitin-editing enzyme that deubiquitinates
TRAF6 to inhibit the release of NFκBf r o mI κB, thus
inhibiting subsequent NFκB-mediated gene transcription
[3, 44]. IRF4 inhibits TLR signaling by competing for
the same binding site on MyD88 with IRF5 [45]. IRF5
engages MyD88 downstream of TLR stimulation in order to
promote production of proinﬂammatory cytokines. By IRF4
competing with IRF5 for binding, it inhibits the activation of
IRF5 thus impairing IRF5-mediated cytokine production.
3.TLRs inAutoimmunity
We know that TLRs are involved in protective immunity to
invading microorganisms, but what are the consequences of
misregulated TLR activation—meaning situations in which
the TLR pathways are turned on too easily or activated by
self-stimulus? The work of several groups suggests that in
such instances, autoimmunity ensues. The resulting pheno-
typeischaracterizedbytheproductionofautoantibodiesand
tissue destruction. TLRs have been identiﬁed as instigators
in type I diabetes, rheumatoid arthritis, and systemic lupus
erythematosus.
ThenucleicacidbindingTLRsareparticularlyimplicated
in SLE, an exceedingly complex and variable disorder.
SLE is a systemic autoimmune disease characterized most
commonly by antinuclear antibodies (ANAs). This disease is
believed to aﬀect at least 5 million individuals worldwide.
Modern, eﬀective treatment options are lacking for SLE,
in that the primary treatment methods are currently corti-
costeroids, antimalarial, or anti-inﬂammatory drugs. There
has not been an FDA-approved lupus treatment in over 40
years. The issue with this is the lack of identiﬁcation of a
“ c o m m o nd e n o m i n a t o r , ”s ot os p e a k ,f o ra l ll u p u sp a t i e n t s ,
which relates back to the complexity of the disease. However,
the relatively new idea that Toll-like receptor pathways
play crucial roles in lupus pathogenesis shows promise for
potential drug targets.
The role of nucleic acid binding TLR 7 has become
quite apparent in both animal models of the disease and
human patients. This receptor promotes autoantibodies and
cytokines responsible for chronic inﬂammation [14, 46, 47].
One particularly important animal model at the forefront of
these observations has been the BXSB mouse. This model
was derived from a cross between C57BL/6 and SB/Le
inbred strains, which resulted in male mice expressing an
accelerated, lupus-like autoimmune disease phenotype char-
acterized by production of ANAs and circulating immune
complexes causing severe glomerulonephritis [48, 49]. Sev-
eral subsequent studies have shown that the reason for the
male bias in these mice was due to an X-to-Y chromosomal
translocation of a gene cluster known as Y autoimmune
accelerator (Yaa) and that the primary contributor to this
accelerated autoimmunity is TLR 7 overexpression [16, 17].
FcγRIIB−/− mice have a characteristic lupus-like phenotype
with autoantibodies directed towards chromatin. However,
FcγRIIB−/− mice that also expressed Yaa exhibited a shift
in autoantibody speciﬁcity from an antichromatin to an
antinucleolar ANA pattern, consistent with an observed
shift from chromatin to RNA-binding speciﬁcities [50]. This
work further indicates a role for TLRs, in particular TLR
7, in the development of a speciﬁc autoimmune phenotype.
Other groups have also described nucleic acid-binding TLR
involvement in the production of autoantibodies. In one
case in particular, Kono and colleagues ablated TLR 3, 7,
and 9 signaling in B6-Faslpr and BXSB mouse models and
showed that these mice expressed decreases in autoantibody
production [51].
Additional work has shown that defective apoptotic cell
clearance is common among SLE patients, and this leads to
development of antinuclear antibodies [52–54]. Our labo-
ratory hypothesized that ineﬃcient clearance of apoptotic
debris triggers nucleic acid-binding toll-like receptors, which
confer the B-cell response and subsequent ANA production.
Injection of syngeneic late apoptotic thymocytes into wild
type B6 mice led to anti-dsDNA and antihistone antibody
production whereas injection into MyD88−/− mice had
no eﬀect, suggesting that TLR stimulation is important
in development of anti-dsDNA antibodies in situations of
late apoptotic cell excess. Further studies using TLR 7-
and TLR 9-deﬁcient recipients of late apoptotic thymocytes
showed that TLR 9 had no bearing on the development
of anti-dsDNA and antihistone antibodies in this model,
but TLR 7 did [55]. Moreover, the evidence suggested
that TLR 7 promoted deposition of immune complexes in
the renal glomeruli of these mice, possibly by inﬂuencing
antichromatin antibody isotype. These studies suggest an
important role for TLR 7 in the development of autoreactive
antibodies and promotion of early events leading renal
pathogenesis.
The DNA-binding TLR 9 has also been heavily studied
in connection with murine lupus. TLR 9 deﬁciency in some
lupus models including MRLlpr/lpr mice can variably lead
to reductions or alterations in antichromatin antibodies;
however, TLR 9 deﬁciency paradoxically leads to disease4 Mediators of Inﬂammation
exacerbation in multiple models [13, 14, 56–58]. In contrast,
TLR3 deﬁciency failed to modify disease in MRLlpr/lpr mice
[14].
Considering endogenous self-stimuli, then, murine stud-
ies indicate a central pathogenic role for TLR 7 in lupus
pathogenesisandacomplexoverallprotectiveroleforTLR9.
Although endogenously triggered TLR 3 does not appear to
drive lupus in the murine models investigated thus far, this
particular TLR may play important roles in the promotion
of lupus by environmental stimuli such as certain viral
infections [59].
Most importantly, in addition to studies using mouse
models, connections between TLRs and human lupus have
also been identiﬁed. One of the most striking connections
is the presence of elevated IFN-α as well as a Type I
IFN gene signature in lupus patients [60, 61]. IFN-α is
a key player in disease progression and severity and has
even been shown to induce the production of autoan-
tibodies when administered to nonautoimmune patients
[62]. Another interesting ﬁnding was remission of SLE
in a patient, which was attributed to unresponsiveness
t ob o t hT L R7a n d9s t i m u l a t i o na f t e rd e v e l o p m e n to f
common variable immunodeﬁciency- (CVID-) like disease
[63]. Several groups have identiﬁed SNPs in the TLR 9 gene
buthavediscoveredthatthereisnocorrelationbetweenthese
polymorphisms and SLE [64–67]. Although there was no
correlation with particular SNPs, other groups showed that
there was an upregulation of TLR 9 expression in B cells
of lupus patients lending credence to the idea that TLR 9
could be involved in autoantibody production [68–70]. This
ﬁnding led to the notion that the signaling proteins may
be at fault in disease. Recent advances in genetic analysis
techniques have allowed for the identiﬁcation of a large
number of genes (more than 25) that are associated with
human lupus. At least three of the lupus-associated genes
are involved in TLR signaling, including IRF5, IRAK1, and
TNFAIP3 [71–74]. The implication of these genes in lupus
patients further indicates a role of TLRs in the disease
phenotype. Whether enhanced stimulation of the TLRs or
genetic factors altering the signaling cascade are at fault,
the accumulation of evidence implies that TLR pathways
do, in fact, play a role in the pathogenic process of SLE
and remain excellent candidates for therapeutic targets to
alleviate disease.
Although most studies related to Toll-like receptors in
SLE have focused primarily on the nucleic acid-binding
TLRs, there is still a potential role for other TLRs in
autoimmune disease. Komatsuda et al. looked at mRNA
expression of several TLRs in peripheral blood mononuclear
cells (PBMCs) from SLE patients. These studies indicated
a slight increase in mRNA of TLR2, 7, and 9 in the lupus
patients compared to healthy controls [75]. Additionally,
others have reported an important role for TLR2 and 4 in the
production of autoantibodies in the B6lpr/lpr autoimmune
mouse model [76]. In these studies, TLR2- and TLR4-
deﬁcient B6lpr/lprmice expressed lower titers of autoantibod-
ies, excluding those directed towards nucleosome proteins.
This shows that other TLRs could be candidates for targeted
therapy in autoimmunity as well.
4. TLRs asTherapeutic Targets
Signiﬁcant evidence supports the involvement of TLRs in
multiple disease processes, including Type I diabetes, RA,
and SLE. The assertion that TLRs play a role in disease
pathogenesis, with lupus in particular, indicates potential
for therapeutic intervention by targeting these molecules
or their signaling pathways. Since there are several proteins
involved in TLR signaling, there are a number of targets
that may be utilized for potential drugs. Some of the
possibilities include, but are not limited to, development of
TLR antagonists, inhibitors of downstream signaling events,
activation of natural inhibitory molecules, or blockade of the
eﬀector molecules produced. Here we will discuss reports
that highlight the potential usefulness of these diﬀerent types
of drugs.
ThedevelopmentofTLRantagonistsforthenucleicacid-
binding TLRs has proven to be a tedious process due to
the similarity between eukaryotic and noneukaryotic nucleic
acids. Despite this diﬃculty, Barrat and colleagues have
developed immunoregulatory DNA sequences (IRS) that
can bind TLR 9 but inhibit its activation and downstream
eﬀects. They have shown that these inhibitory ODNs can
relieve inﬂammation in multiple scenarios. In one instance,
mice injected with immunostimulatory sequences (ISSs)
and D-galactosamine developed severe inﬂammation and
died within days. However, when coinjected with the IRS,
inﬂammation was decreased and mouse survival was pro-
longed [77]. Similar experiments demonstrated the same
eﬀect with TLR 7 as well. In addition to these studies,
the same group developed a dual TLR 7/9 inhibitor. This
oligodeoxynucleotide (ODN) was suﬃcient for inhibition
of both TLR 7 and 9 signaling and protection against
inﬂammation. These IRS sequences were also demonstrated
to inhibit the production of IFN-α by human plasmacytoid
dendritic cells (pDC), indicating the eﬀectiveness of these
inhibitors in human cells [78]. Because of the eﬀectiveness
in inhibiting TLR function, Barrat et al. also investigated the
capacity of their ODNs to treat a lupus-prone mouse model.
Several studies had previously established a potential role of
IFN-αintheprogressionofautoimmunityin(NZB ×NZW)
F1 mice [79, 80]. Since IFN-α appears to play a central role
in human SLE [81], this strain was selected as an ideal model
for the application of IRS. IRS injections twice weekly in
(NZB × NZW) F1 mice resulted in decreased ANAs, reduced
glomerulonephritis at nine months, and increased rate of
survival among the treated mice compared to untreated
controls [82].
In addition to the studies by Barrat, two other groups
used other inhibitory ODNs for targeting TLR signaling in
autoimmunity. The ODNs designed by Dong et al. were
injected into (NZB × NZW) F1 mice that were subsequently
analyzed for kidney function and autoantibody production
characteristic of lupus. Their results suggested a similar
capacity of these inhibitory ODNs to minimize glomeru-
lonephritisandreduceautoantibodiesdirectedtowardsDNA
[83]. Pawar et al. used IRS sequences as TLR 7 and 9
inhibitors in MRLlpr/lpr m i c ea n ds h o w e dar e d u c t i o ni n
inﬂammatory cytokine levels and autoantibody titers, asMediators of Inﬂammation 5
well as a decrease in resulting tissue damage [84]. These
experiments using inhibitory ODNs in treating lupus-prone
animal models suggest strong potential for treatment of
human lupus and other autoimmune diseases by targeting
TLRs.
Other potential therapeutic targets include the down-
stream signaling proteins involved in the TLR signaling
cascade. There are a number of potential targets for this
intervention including MyD88, TRAF6, and IRAK1 and
4. MyD88 is the common adaptor protein in most TLR
signaling [85]. Since both TLR 7 and 9 utilize this protein,
it is an excellent target to decrease the signaling that takes
place in lupus. Two independent groups have shown that
inhibiting MyD88 impairs the phosphorylation/activation of
downstream kinases [86]a n dN F κBa c t i v i t y[ 87]. Bartfai
and colleagues developed a chemical mimic to the three
amino acid sequence at the conserved BB-loop of the TIR
domain of MyD88. The results of this mimic showed an
inhibition of MyD88 and IL-1RI interaction by ablating
phosphorylation of MAP kinases [86]. Loiarro et al. describe
a similar mimic; however, they employ a peptide sequence
instead of a chemical mimic. This inhibitor showed similar
inhibition of MyD88 signaling indicated by impaired NFκB
activity [87]. They also went on to show that not only
do these peptides inhibit dimerization of MyD88, but also
inhibit the recruitment of IRAK1 and IRAK4 [88]. In view
of the fact that MyD88 is a central mediator in TLR 7 and
9 signaling, these inhibitors of MyD88 dimerization and
recruitment of essential kinases couldprove to be aneﬀective
treatment option in lupus by abolishing the aberrant TLR
signaling that induces the elevated type I IFN levels and
persistent inﬂammation.
Another potential target for minimizing damaging TLR
signaling is IRAK4. Brieﬂy, IRAK4 is a kinase that interacts
withMyD88andTRAF6andisassociatedwiththeactivation
of the downstream transcription factors in TLR signaling.
Based on IRAK4-deﬁcient animal models, this kinase has
been shown to be indispensible in TLR signaling [89, 90].
BecauseofthisideathatIRAK4isnecessaryforproductionof
eﬀectors in a TLR-dependent manner, it has been subjected
to targeted therapy. However, IRAK4 inhibitors developed to
date have yet to be analyzed for eﬃcacy in animal models
[91–94].
The last actively studied therapeutic approach we will
discuss targets the end-product eﬀectors of TLR signaling as
opposed to the signaling cascade itself. An important target
thatisnowacceptedtobecharacteristicofSLEisIFN-α.This
cytokine is found in elevated levels among lupus patients,
and high levels associate with worsened measures of disease
activity [81]. Due to the apparent pathogenic nature of IFN-
α, inhibitory monoclonal antibodies have been developed
against the cytokine as a treatment for SLE [95]. One such
drug is currently in phase II clinical trials and has shown
promisethusfarinrelievingsymptomsoflupus[96].Among
the TLR and TLR-related targets for therapy in lupus, this
antibody directed towards IFN-α appears to be the most
outstanding thus far.
Currently, active research on this topic is concerned with
negatively regulating molecules that activate TLR-dependent
signaling, but what about activating some of the natural
inhibitory proteins, such as Triad3A, MyD88s, SHP-1, IRAK-
M, IRAK1c, IRF4, and A20? These naturally occurring
inhibitors of the signaling cascade could be targeted for
agonistic drugs. Xie et al. reported that IRAK-M-deﬁcient
miceinjectedwithtumorcellsdevelopincreasedCD4+ T-cell
diﬀerentiation and upregulation of costimulatory molecules
and other activation markers on B cells, compared to
wild-type controls, indicating an inhibitory role for IRAK-
M[ 97]. Although IRAK-M deﬁciency appears to have a
positive role in cancer models, the inverse is likely to be
true for autoimmune situations. Stimulation of production
or activity of IRAK-M may provide another alternative
therapy in SLE. Similarly, promoting the production or
activity of the other endogenous TLR signaling inhibitors,
Triad3A, MyD88s, SHP-1, IRAK1c, IRF4, or A20, could
provide additional options for eﬀective treatment for sys-
temic autoimmunity. Utilizing these endogenous proteins
could provide a new avenue to decrease TLR-mediated
inﬂammation in patients with autoimmune diseases, with
each of these targets allowing a diﬀerent route to decreasing
production of inﬂammatory cytokines and subsequent risk
of tissue damage.
Although the approaches presented here are in the
contextofnucleicacid-bindingTLRs,theproposedstrategies
for TLR signaling inhibition could actually act more globally.
Since most TLRs can signal through the adaptor protein
MyD88, these potential therapeutic targets could prevent
signaling through all TLRs with the exception of TLR 3. The
speciﬁc TLR 7 and TLR 9 inhibitors discussed earlier would
be ideal as a treatment method to avoid a total inhibition
of the ﬁrst line of microbial defense; however, with evidence
revealing potential roles for other Toll-like receptors, namely,
TLR 2 and 4, in SLE, a more widespread inhibition may be
an important aspect worth investigating.
5. Conclusions
Although TLRs are extraordinarily important in pathogen
recognition and normal immune function, including that
of both innate and adaptive arms of the immune system,
theyhavealsobeenascribedcausativerolesinautoimmunity.
Various studies ranging from lupus-prone mouse models, to
genome-wideassociationstudiesinhumanlupuspatients,to
in vitro studies with patient cells have indicated a signiﬁcant
role for nucleic acid-binding TLRs in the progression and
severity of lupus and other autoimmune diseases. From
these studies, we have learned about the involvement of
TLRs in lupus-prone mouse models, the association of
polymorphisms in IRF5, IRAK1, and TNFAIP3 with human
disease,andtheupregulationofTLRsinSLEpatients.Dueto
the accumulation of these data suggesting a detrimental role
of TLR signaling in lupus, eﬀorts are currently underway to
ascertain reliable treatment methods based on the targeting
of TLRs and their signaling counterparts. Inhibition of TLRs
and their signaling pathways have proven to be eﬃcacious
in lupus-prone mouse models and successfully inhibit IFN-
α production by human pDC in vitro. Although the direct6 Mediators of Inﬂammation
TLR antagonists have not been studied in human patients,
inhibitors of IFN-α, a primary downstream eﬀector of TLR
signaling and important disease mediator in SLE, have
been developed and are currently undergoing clinical trials.
Monoclonal antibody treatments have been successfully
utilized in the setting of rheumatic diseases for some time
now and are likely to comprise a new armament the realm
of lupus treatment. Although there has not been a new
drug approved for the treatment of lupus in many years,
current investigation regarding the targeting of TLRs and
their downstream eﬀectors is showing some promise and
warrants high expectations.
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